home · filing · 0001213900-22-063416
8-K filed October 12, 2022, 7:59 PM ET
ticker KTTA
CIK 0001841330
M&A
confidence high
sentiment neutral
materiality 0.75
Pasithea acquires AlloMek for $1.05M cash, 2.7M shares + warrants; adds MEK inhibitor CIP-137401
Pasithea Therapeutics Corp.
Total deal value includes $1.05M cash, 2.7M restricted shares, 1M warrants at $1.88, up to $5M milestones, and royalties.
CIP-137401 is a macrocyclic MEK inhibitor for NF1 and Noonan syndrome; already has FDA orphan-drug designation for NF1.
Plans to file IND in 2H 2023 and initiate Phase 1 trial in NF1; expects synergies with existing MS program.
Daniel Schneiderman appointed CFO effective Oct 11, 2022 with base salary $330K and 300K stock options.
Sellers subject to two-year lock-up; 1.35M shares lock up release at one year, then 112.5K monthly.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Effective 2022-10-11
Filed October 12, 2022, 7:59 PM ET
Effective October 11, 2022, Daniel Schneiderman was appointed to serve as the Chief Financial Officer of the Company.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Daniel Schneiderman was appointed as Chief Financial Officer at Pasithea Therapeutics Corp..
Action appointed
Role Chief Financial Officer
Exact text from the filing
Effective October 11, 2022, Daniel Schneiderman was appointed to serve as the Chief Financial Officer of the Company.
View on SEC.gov
Source: SEC EDGAR
accession 0001213900-22-063416
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.